Clinical Trial: VPD-737 for Treatment of Chronic Pruritus

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus

Brief Summary: A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments

Detailed Summary: The sensation of itch is transmitted to the brain through the nervous system Several chemicals are involved in transmitting this signal This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial The trial will involve once daily pills for 6 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period Patients will also be monitored for safety and will have blood taken for testing and several points during the trial Overall participation will last about 12 weeks
Sponsor: Menlo Therapeutics Inc.

Current Primary Outcome: Visual Analog Scale [ Time Frame: 6 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Verbal Response Scale [ Time Frame: 6 weeks ]

Original Secondary Outcome: Same as current

Information By: Menlo Therapeutics Inc.

Dates:
Date Received: July 19, 2013
Date Started: October 2013
Date Completion:
Last Updated: May 20, 2015
Last Verified: June 2013